Medical and Chemical TOC Members

I, Emmanuel Addo-Yobo, residing in Ghana, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor in the Department of Child Health, Kwame Nkrumah University of Science and Technology, and Honorary Consultant Paediatrician with sub-specialty interest in paediatric pulmonology in the Directorate of Child Health, Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. My responsibilities include general paediatric clinical care, clinical teaching and mentoring of undergraduate and postgraduate medical students. I am the clinical consultant-in-charge of Paediatric Asthma Clinic KATH. I have been involved in many research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies. I do not receive any form of remuneration from any drug companies. I have, however, given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have any proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. (if answer is yes describe briefly)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: My business has an interest in the topics of the Montreal Protocol with regard to patients I attend to with asthma and COPD who may be using MDIs containing ODS where there are no other affordable and effective alternatives. My spouse is a business secretary working with a local financial institution in Ghana and has no interests in matters before the Protocol.
   • Government advice and other policy development: I served as a member ofthe National Expert Committee for the review of Standard Treatment Guidelines for Ghana (2016-2017). My role in this Committee included advising prescribers on safe and cost-effective treatments for asthma and COPD, and other disorders in my capacity as a clinician. I am also currently the chair ofthe National Poliomyelitis Expert Commitee (NPEC).
   • Paid research activities,fellowships or grants: I am currently the country Principal Investigator for a multi -African country asthma study - “Achieving Control ofAsthma in Children in Africa (ACACIA) Study” - and a sub-study on air pollution and asthma – “Children’s Air Pollution Profiles in Africa (CAPPA) Study”, aspects of which involve information on use of asthma medications in children.
   • Other interests: None
5. The source offunding for my participation in the work of TEAP: The source offunding for my participation in the work ofthe Medical and Chemicals Technical Options Committee has been the Ozone Secretariat ofthe United Nations Environmental Programme (UNEP).
6. Pursuant to paragraph 11 oftheCOI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Emmanuel Addo-Yobo
Date: 2022-03-08

I, Fatma AlShatti, residing in Kuwait, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a consulantant to the international Ozone Committee of Kuwait Public Authority of Environment,having previously worked in the Petroleum Private Sector.My responsibilities are to ensure that information from Kuwait is provided.to help the gulf to understand and comply with Montereal Protocal.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have) proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. (if answer is yes describe briey)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (if answer is yes describe briey)NO
   • Employment, consultancy, directorship or other positions: (if answer is yes describe briey), I have an intrest in the work of the MCTOC and the outcomes of the Montreal Protocol beacuse of my consulting role with KEPA.
   • Government advice and other policy development: (if answer is yes describe briey) Yes in my role I provide consulting advice to the Kuwait Government about the Montreal Protocol, inculding about compliance requirements.
   • Paid research activities, fellowships or grants: (if answer is yes describe briey)NO
   • Other interests: (if answer is yes describe briey) NO
5. The source of funding for my participation in the work of TEAP is UNEPs Ozone Secretariat.
6. Pursuant to paragraph 11 o the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed:Fatma AlShatti
Date: 2022-03-12

I, Paul Atkins, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a retired pharmaceutical executive who has worked on the Development and Commercialization on inhalers (MDI's and Dry powder Inhalers) for over 30 years. I currently serve as Executive Chairman of Nob Hill Therapeutics, an early stage company that is developing a novel dry powder nebulizer. I also consult for several pharma companies in the inhaler space.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: My wife and I have have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. Specifically we hold stock in 3 companies that have an interest in inhaler development, namely Novartis, Astra Zenecca and GSK.
   • Employment, consultancy, directorship or other positions: My wife is a senior executive in Astra Zenecca.
   • Government advice and other policy development: My responsibilities at the USEPA may include providing information and advice to stakeholdersGovernment advice and other policy development: N/A
   • Paid research activities, fellowships or grants: N/A
   • Other interests: N/A
5. The source of funding for my participation in the work of TEAP is personal funding
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed:Paul Atkins
Date: 2022-02-28

I, William Auriemma, nominated by and residing in The United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I serve as the Chie Executive Officer of Diversified CPC International, Inc., engaged in the supply of aerosol propellants to the consumer products industry. We do extensive work in determining commercial viability of “next generation” of propellant systems. My role as Past Chairman of the Household & Commercial Products Association allows for direct interaction with U.S. regulatory agencies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies.
   • Financial interests: I do not ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: My company works closely with major U.S. based manufacturers of low GWP substances and is the marketing and distribution arm of these products to the aerosol and medical device industries.
   • Government advice and other policy development: See above under Item c.
   • Paid research activities, fellowships or grants: None.
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is our company, Diversified CPC International, Inc. and they will bear all related costs.  There are no consulting fees involved.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: William Auriemma
Date: 19th April 2021

I, Dr. Christian SEKOMO BIRAME, residing in Rwanda, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a the Director General of the National Industrial Research and Development Agency (NIRDA) and part time Lecturer at the University of Rwanda (UR) in the College of Science and Technology (CST) / School of Science (SoS) / Department of Chemistry. I use to teach the following modules: Analytical Chemistry I & II; Environmental Chemistry I, Fundamental of waste management at undergraduate level and Water Quality Principles and Management; Wastewater Treatment and Disposal; Supervision of laboratory work and BSc final year project as well as MSC and PhD thesis. Beside my daily university workload I use to conduct many consultancies work for the Ministry of Environment and REMA mainly related with waste management in general (water quality analysis; Hazardous chemical waste management (POPs, PCBs and Hg). Recently I have worked with a team of IT specialist in the development of an IT system for ODS management in Rwanda for REMA.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I have an interest to conduct consultancy services in the topics of the Montreal Protocol because my potential client is also interested in these topics. I consult for an organisation that supports the Montreal Protocol in phasing out controlled substances.
   • Government advice and other policy development: See above under c.
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee will be provided by the Ozone Secretariat to support travel and accommodation when I will be attending MCTOC planned meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Dr. Christian SEKOMO BIRAME
Date: 2022-03-09

I, Olga Blinova, residing in Russian Federation, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work for the institution as a Research Fellow of the Laboratory of Zooanthroponoses. My responsibilities include studies in the area of the impact of climate change on epidemiology of zooanthroponoses
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: NO
   • Government advice and other policy development: NO
   • Paid research activities, fellowships or grants: NO
   • Other interests: NO
5. The source of funding for my participation in the work of TEAP is UNEP
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Olga Blinova
Date: 2022-02-22

I, Stephen Burns, residing in United Kingdom, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Global Project Leader at Astrazeneca. My responsibilities include the development of new medicines for treatment of Respiratopry and Immunological illness.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have shares in an entity with an interest in the subject matter of the meeting or work. I hold shares and share options with AstraZeneca
   • Employment, consultancy, directorship or other positions: I am employed by AstraZeneca
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is AstraZeneca
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Stephen Burns
Date: 2022-02-22

I, Nicholas Campbell, residing in France, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests include the following
   • Proprietary interests: I do not have a proprietary interest in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies.
   • Financial interests: I have stock options in ARKEMA SA. ARKEMA SA is a producer of HCFCs, HFCs and HFOs.
   • Employment, consultancy, directorship or other positions: I am Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union. I am also a member of the World Bank’s Ozone Operations Resource Group.
   • Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants: I do not receive any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance, a hydrofluorocarcarbon or an alternative to a proposed use of an ozone depleting substance.
   • Other interests: I do not have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. ARKEMA SA supports my participation and travel on MCTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed: Nicholas J. Campbell
Date: 2022-02-22

I, Andrea Casazza, residing in Italy, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am responsible of the technical product development of pharmaceutical products for Chiesi Farmaceutici. My organization is in charge to follow chemical, formulation and device development of inhalation, injectable and oral products. The development of inhalation products is of particular interest and this include the use of propelants for the development of pressurised metered dose inhalars (pMDI's)
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. (if answer is yes describe briefly)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (if answer is yes describe briefly)
   • Employment, consultancy, directorship or other positions: as employer of Chiesi Farmaceutici I have interest in the topic of Montreal Proptocol becouse we are manufacturing pMDI products containing HFC and Dry Powder for inhalation (DPI); we are committed to develop alternative low global warming potential pMDI's.
   • Government advice and other policy development: No
   • Paid research activities, fellowships or grants: No
   • Other interests: No
5. The source of funding for my participation in the work of TEAP is from Chiesi Farmaceutici
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Andrea Casazza
Date: 2022-03-18

I, Richard Cooke, residing in Canada, a Member of the Medical and Chemicals Technical Options Committee, of MBTOC till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a semi-retired international consultant active in assignments for UNDP and UNIDO implemented MP MLF and GEF financed projects as well as periodic advisory assignments with other international development organizations and private sector companies. These activities generally cover the development and inplementation of convention based chemicals management and climate project funded by or through international agencies related End of Life ODS/HFC management, POPs legacy and contaminated site management, and assessment/qualification of technologies supporting these areas. Associated with this work I am periodic contributor to seminars, workshops and webinars on these topics. As has been the practice over 10 years of probono particupation in TEAP Destructuction Task Force and more recently MCTOC membership, I maintain active communication with the lead co-chair of the MCTOC on my current activies to ensure these are known and seek advice on any issues that might be percieved as a COI.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Contact work for UNDP related to development of strategies and globa partnerships realted to End of Life ODS/HFC management.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: 1. General interest and participation in NGO activities associated with natural landscape/Habitat protection, and support for public review processes associated with fossil fuel resource development, all in Canada. 2.- Corporate minority financial interest in information management company involved in waste management and climate accounting data management services
5. The source offunding for my participation in the work of TEAP is Man-West Environmental Group Ltd a company that I am the owner of. Such funding is treated as a general non-revenue generating contribution of knowledge and expertise to a global environmental issue.
6. Pursuant to paragraph 11 oftheCOI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed:Richard Cooke
Date: 2022-03-03

I, Jin Fang, residing in China, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am (Professor of Institute of respiratory diseases, Guangzhou Medical University). My responsibilities include (Research and development of inhalation preparation).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I (have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
     I am one of the inventors of two MDI inhalant related patents. In China, the patent inventor does not have the patent rights and interests. Although the patents have been authorized for many years, I have not obtained any economic benefits.
     Details of authorized patents are as follows:
     1. The invention relates to an inhalation pressure quantitative aerosol pharmaceutical composition and a preparation method thereof, Jin Fang; Wen Cong; Li Lixin, 2021-4-27
     2. A quantitative inhalation aerosol of benzcycloquinium bromide and its preparation method, Jin Fang; Zhao Shuqiang; Zhang Liu; Deng Wanding; Ding Hao; Wen Shouming;Zhao, 2012-2-22
   • Financial interests: I ( do not have) ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (if answer is yes describe briefly)
   • Employment, consultancy, directorship or other positions: (if answer is yes describe briefly) I am currently a member of the Chinese Pharmacopoeia Committee, participating in the formulation of Chinese Pharmacopoeia related to inhaled preparations; the chairman of the Pharmaceutical Engineering Committee and participates in the conference organization of pharmaceutical industry including inhaled preparations. Both the above special committees are non-profit organizations.And as PI in Institute of respiratory diseases, Guangzhou Medical University, engaged in inhalation related scientific research work.
   • Government advice and other policy development: (if answer is yes describe briefly) I drafted China's National Strategy forCFCs Elimination in MDIs and theAction Plan forReplacing Halon in Chinese Metered Dose Inhaler.
   • Paid research activities,fellowships or grants: (if answer is yes describe briefly) I have been funded by the National Pharmacopoeia Committee to study the general principles of inhalation preparations, and funded by the Ministry of science and technology ofthe People’s Republic ofChina to carry out the research on the pharmaceutical compositions and preparation methods of benzocycloquinium bromide inhalation aerosol, salbutamol sulfate aerosol and inhalation pressure quantitative aerosol.
   • Other interests: (if answer is yes describe briefly)
5. Self-funding or by MCTOC (funding for travelto meetings will be provided by UNEP's Ozone Secretariat)
6. Pursuant to paragraph 11 oftheCOI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Jin Fang
Date: 2022-03-04

I, Maureen George, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor at Columbia University School of Nursing. My responsibilities include leading an independent program of research in chronic respiratory diseases in vulnerable populations, serving as the Interim PhD Program Director, teaching in the PhD a program, and meeting other service requirements.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. Honoraria received for advisory/consultant roles with Astra Zeneca, Genentech, Sanofi/Regeneron and Teva Pharmaceuticals. Speaker for Astra-Zeneca and Genentech
   • Employment, consultancy, directorship or other positions: None
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is my employer,Columbia University School of Nursing,for in-kind contributions to her committee participation and travelto MCTOC meetings
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Maureen George
Date: 2022-03-09

I, Kathleen Hoffman, nominated by United States of America, residing in United States of America, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Sotera Health as Sr. Vice President of Global Environmental, Health and Safety. My responsibilities include leading the company’s global environmental, health, safety and security management program across the three difference Sotera business units.  Other responsibilities include oversight of various regulatory actions and participation with various government and trade association groups on regulatory and technical topics.  Sotera is a holding company that leads in the contract sterilization and testing services for the medical device and pharmaceutical industries. We utilize ethylene oxide and radiation for the sterilization and bio reduction of medical products, cosmetics and food products.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: See response to #2.
   • Government advice and other policy development: See response to #2.
   • Paid research activities, fellowships or grants:  None
   • Other interests:  None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is by a voluntary basis.  However, such funding is very limited because my participation is mainly done on a remote basis.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:             Kathleen Hoffman
Date:               April 21, 2021

I, Jianxin Hu, residing in China, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a professor in Peking University, Beijing China. My responsibilities include researching on environmental management on Chemicals.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: No
   • Government advice and other policy development: I am advising the government to develop country program and sector plan for management of ODS and HFCs
   • Paid research activities, fellowships or grants: researching projects on management of ODS and HFCs in China.
5. The source of funding for my participation in the work of TEAP is UNEP
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed: Jianxin Hu
Date: 2022-03-03

I, Ryan Hulse, residing in United States of America, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Research and Development Director at Honeywell International. My responsibilities include leading the applications team in the development of new products in the areas Aerosol, Solvent, Refrigerants and Foam Blowing Agents.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). As part of my work at Honeywell I have developed aerosol and solvent alternatives to CFC and HCFCs. These rights for the patents are wholly owned by Honeywell.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of TEAP is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Ryan Hulse
Date: 2022-02-22

I, Robert James Meyer, MD, residing in United States of America, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a regulatory expert in the use of propellants in medicinal inhalation products for the treatment of asthma and COPD, having worked in the past both at the US Food and Drug Administration and at a major multinational pharmaceutical company (Merck, Sharpe and Dohme).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am a principal in Drug and Biological products strategic regulatory consulting at Greenleaf Health in Washington DC. My client work does not represent a conflict with my work on the MCTOC
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is self-pay (with travel covered by my employer)
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Robert James Meyer, MD
Date: 2022-02-22

I, Rabinder N Kaul, nominated by, and residing in India, appointed as member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXXI/3 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I presently work for SRF Limited as a consultant. I am also Secretary of REGMA, an industrial association of refrigerant gases manufacturers in India.  My responsibilities include work related to the Montreal Protocol and related MEAs and the regulatory issues.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   • Financial interests: I do have some shares in an entity with an interest in the subject
   • Employment, consultancy, directorship or other positions: I am also Secretary of the Refrigerant Gas Manufacturers Association (REGMA)
   • Government advice and other policy development: Do not provide advice on significant issues to a Government in respect of policy.
   • Paid research activities, fellowships or grants: I do not receive paid research activities or any fellowships /grants relevant to the TEAP activity.
   • Other interests: No other interests related to the subject matter of TEAP/Montreal Protocol
5. The source of funding for my participation in the work of the TOC and TEAP’s Task Force on Unexpected emissions of CFC 11. The travel and stay is funded by the Ozone Secretariat as Article 5 participant.   Professional services are however voluntary.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TOC and TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:   Rabinder N Kaul
Date:    April 15, 2021

I, DR JAVAID AHMED KHAN nominated by PAKISTAN residing in PAKISTAN  as a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor and Consultant Chest Physician at the Aga Khan University. My responsibilities include taking care of patients with respiratory diseases including asthma and COPD. I also take part in educational activities involving doctors, medical students and general public. I am also involved in research work related to respiratory medicine and tobacco control.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.  YES
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work
   • Employment, consultancy, directorship or other positions:  I am chair National Alliance for Tobacco control.
   • Government advice and other policy development: I do advise to government when my opinion is requested in relation with control of NCD in Pakistan. I advise government on various tobacco control measures. As Pulmonologist I do raise my voice on better quality of respiratory care and availability of low cost inhalers for asthma and COPD patients
   • Paid research activities, fellowships or grants:  As researcher I do receive grants from various funding agencies but mainly related to tobacco control in Pakistan
   • Other interests:  My other interests are climate change and global warming. I am a strong advocate for tree plantation in the country.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee that involves travel is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr Javaid Khan
Date: May 19 2021

I, Andy Lindley, residing in United Kingdom of Great Britain and Northern Ireland, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an independent consultant providing services to Koura Global and EFCTC. My responsibilities include the European Fluorocarbon Technical Committee (EFCTC) mainly focused on HFCs and HFOs, their applications and EFCTC website content development and newsletter production.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. (if answer is yes describe briefly)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (if answer is yes describe briefly)
   • Employment, consultancy, directorship or other positions: (if answer is yes describe briefly) I am an independent consultant providing services to Koura Global and the European Fluorocarbon Technical Committee (EFCTC)
   • Government advice and other policy development: (if answer is yes describe briefly) No
   • Paid research activities, fellowships or grants: (if answer is yes describe briefly) No
   • Other interests: (if answer is yes describe briefly)
5. The source of funding for my participation in the work of TEAP is none as no funding is required for my participation as a corresponding member
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Andy Lindley
Date: 2022-02-23

I, Gerald McDonnell, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a senior director of microbiological quality and sterility assurnace with Johnson and Johnson. My responsibilities include the development and use of sterilization technologies, including antimicrobial gases.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I work for a company that utilizes sterilization technologies and am on the board of directors for AAMI, a nonprofit organization for the development of consensus standards, both national and international, for the medical device industry, as well as practical information, support, and guidance for healthcare technology and sterilization professionals.
   • Government advice and other policy development: periodic and related to the areas of cleaning, disinfection, and sterilization.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is my employer, Johnson & Johnson.
6. Pursuant to paragraph 11 oftheCOI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Gerald McDonnell
Date: 2022-03-08

I, Dr. B. Narsaiah, nominated by the Government of India, residing in India, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Dr. B. Narsaiah, Chief Scientist & Head (retired), Fluoroorganic division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad – 500007, India. My responsibilities included development of technologies for ozone friendly chemicals and Synthesis of novel fluorinated molecules of biological interest. As I am superannuated from service, I am extending my expertise in Telangana state Environmental Impact Assessment Authority (TSEIAA) committee in giving environmental clearance to various projects like expansion of pharmaceutical industries, mines related to granites, sand, multiplex buildings under specified guidelines. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests1, and those of my personal partner and dependents, include the following 
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (Development of technologies for alternatives to ozone depletion chemicals)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work..
   • Employment, consultancy, directorship or other positions: I have an interest to extend consultancy services to the proposed activities in TEAP.
   • Government advice and other policy development: I have an interest to extend consultancy services to the proposed activities in TEAP. 
   • Paid research activities, fellowships or grants: Based on the options available to extend advisory services, I will coordinate paid research activities. 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is through the Ozone secretariat of the Montreal Protocol, which will fund my participation .
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:Dr.B.Narsaiah
Date:April20,2021

I, Timothy Noakes, nominated by United Kingdom, residing in United Kingdom, a (member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Koura as a global technical expert in Medical Propellant gases. My responsibilities include providing technical support to pMDI industry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   • Employment, consultancy, directorship or other positions: I am employed by Koura, the global leader in supplying medical propellants, and developing new ones.
   • Government advice and other policy development: None (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development)
   • Paid research activities, fellowships or grants: None (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is paid by my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Timothy J. Noakes
Date:   08/04/2021

I, John G. Owens, residing in United States of America, Consulting Expert of the Halons Technical Options Committee, and Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed as a lead research specialist for 3M Company, Saint Paul, Minnesota, USA. 3M Company has an interest in the topic of the Montreal Protocol because it is a manufacturer of technologies which formerly used ozone depleting substances and manufactures alternatives to ODSs.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of stock in my employer, 3M Company, which is an entity with an interest in the Montreal Protocol as stated above. Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8.
   • Employment, consultancy, directorship or other positions: Except for my employment at 3M Company, neither I nor my spouse are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   • Government advice and other policy development: Neither I nor my spouse provide advice to a government or for other policy development.
   • Paid research activities, fellowships or grants: Neither I nor my spouse are recipients of any paid research activities, fellowships or grants.
   • Other interests: Neither I nor my spouse have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. The source of funding for my participation in the work of TEAP is my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: John G. Owens

Date: 2022-02-01

I, José Ignacio Pons, residing in USA, a co-chair of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11 and a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am president of Spray Quimica CA. My responsibilities include production of industrial aerosols.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None.
   • Other interests: Recovery of the Ozone layer and mitigation of Climate Change
5. The source of funding for my participation in the work of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11 is None.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:José Ignacio Pons
Date: April 19th 2021

I, John Pritchard, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am acting as an independent consultant to clients developing respiratory drugs, delivery systems and digital healthcare, trading under the company name of Inspiring Strategies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: We do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: My wife and I have minority ownership of shares in various pharmaceutical companies who develop, manufacture and sell respiratory products that are impacted by decisions taken under the Montreal Protocol.
   • Employment, consultancy, directorship or other positions: : I consult to a variety of clients, some of whom may be commercially impacted by decisions taken under the Montreal Protocol. In particular, I am a non-Executive Director for Cardiff Scintigraphics, and a Director of iPharma, both contract research organisations providing formulation development and testing of inhaled products. In addition, I am a Director of Acu-flow, a company developing novel nebuliser technology and sit on 3 scientific advisory Boards for companies involved in the development of respiratory therapies.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. I receive no funding for my participation in the work of TEAP. Travel expenses might in the future be supported either by client relationships or the UK Government.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: John Pritchard
Date: 2022-03-02

I, Rabbur Reza, nominated by Bangladesh (A5), a member of the Medical and Chemical Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties inDecision XXIV/8.
2. I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh, as Managing Director at Nuvista Pharma Ltd., Bangladesh and as Chief Executive Officer of Sanofi Bangladesh Limited. As the operational leader I am overseeing these Company’s business operations, which include pharmaceutical formulation and raw material manufacturing & quality control, research & development, regulatory affairs, training (learning & development management), sales, marketing and brand management, distribution, international business development, informational technology, medical affairs, project management, human resources etc.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: My employer Beximco Pharmaceuticals is the largest medical inhalers (MDI & DPI) manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. I have no proprietary interest in alternatives or substitutes to ODS.
   • Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
   • Employment, consultancy, directorship or other positions: I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh, as Managing Director at Nuvista Pharma Ltd., Bangladesh and as Chief Executive Officer of Sanofi Bangladesh Limited. I also serve as a director on the board of BioCare Manufacturing Sdn Bhd., Malaysia. BioCare is involved in manufacturing MDIs. My spouse is a medical practitioner and has no interest in matters before the Protocol. d. Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. UNEP’s Ozone Secretariat funds my travel expenses for participation on MTOC. 6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Signed:Rabbur Reza
Date: 9th March 2022

I, David Sherry, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee, of MBTOC till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Co-Director and co-owner of Nolan Sherry and Associates Ltd (NSA). NSA specialises in the chlorine and fluorine chemical industries, providing technical, commercial, strategic and regulatory advice to the chemical industry, trade associations and government organisations. My responsibilities have included studies on HFOs and CTC, chloromethanes, chloroethanes, the commercial outlook for CTC; technical expertise in patent law, due diligence audits of CDM beneficiaries, provision of estimated emission rates for various chlorocarbons to various atmospheric researchers, and various evaluation and monitoring projects for UNMFS, UNDP, and World Bank.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership and shares or bonds in an entity with an interest in the subject matter of the meeting or work. (co-owner of NSA Ltd as described above)
   • Employment, consultancy, directorship or other positions: see above
   • Government advice and other policy development: (see above)
   • Paid research activities, fellowships or grants: none
   • Other interests: (none relevant)
5. The source of funding for my participation in the work of the MCTOC and the CFC-11 Task Force is the UK Department of Environment, Food, and Rural Affairs (DEFRA), who fund specific travel and hotel costs with limited DSA. As a self-employed consultant, the time, medical requirements for travel, and cost of my contribution to the CFC-11 Task Force and to MCTOC is self-funded
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines, and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: David Sherry
Date: 2022-03-02

I, Peter Sleigh, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed as a Regulatory Manager by Mexichem UK Limited (Which trades as Koura), a producer and distributor of fluorinated products. My responsibilities include ensuring regulatory compliance particularly in Europe. Mexichem UK Limited/Koura has an interest in the topics of the Montreal Protocol because they sell fluorochemicals controlled by the protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am employed by Mexichem UK Limited, this role includes being Vice Chair of the European FluoroCarbon Technical Commitee (EFCTC) an industry association for European Fluorocarbon Producers on behalf of Koura
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None, apart from being employed by Mexichem UK limited
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is as part of my day to day Regulatory Manager role for Mexichem UK Limited/Koura.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Peter Sleigh
Date: 2022-03-02

I, Jørgen Vestbo, residing in Denmark, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of Respiratory Medicine at the University of Manchester, Manchester, UK. My responsibilities include research and teaching in respiratory medicine and management of patients; my area of focus is on chronic obstructive pulmonary disease (COPD) and inhaled therapies. I also see respiratory outpatients in a clinic in Copenhagen, Denmark.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I have received honoraria from pharmaceutical companies (ALK-Abello, AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Novartis and Teva) for advising and presenting. All work is being invoiced through a Danish tax registered one-man company, Vestbo medical, VAT Reg No 21215430.
   • Government advice and other policy development: No
   • Paid research activities, fellowships or grants: : I have previously held grants from GSK and together with a junior researcher in my group (Alexander Mathioudakis) I hold a grant from Boehringer-Ingelheim UK (£70,000).
   • Other interests: No
5. The source of funding for my participation in the work of TEAP is personal.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Jørgen Vestbo
Date: 2022-02-22

I, Kristine Whorlow, nominated by the Australian Government, residing in _Melbourne, Australia, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I retired as the CEO of the National Asthma Council Australia in 2017. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns to promote community education on asthma for patients and health professionals. I was also responsible for conducting outreach education activities in Asia Pacific. I am currently the First Vice President of the Global Airways and Allergy Patient Platform (GAAPP), the only global patient organisation in this field whose main role is to support existing and emerging patient organisations dedicated to patient support and advocacy in airways disease and allergy. I have recently joined the advisory board of a new medical respiratory device company, Respia.
3. My responsibilities on the board of GAAPP and the advisory board of Respia include general advice on governance, financial management, strategic planning, communication and the respiratory field.
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
5. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: none relevant.
   • Government advice and other policy development: I occasionally provide general advice to the National Asthma Council Australia on some of the issues considered by MCTOC, e.g. GWP of inhalers, based on MCTOC’s published reports.
   • Paid research activities, fellowships or grants: none.
   • Other interests: none relevant.
6. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal cost.
7. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
8. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
9. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
10. I understand that this DOI will expire no later than one year after I have signed it.

Name: Kristine Whorlow AM
Date: April 21, 2021

I, Gerallt Williams, residing in France, Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Director at Aptar Pharma, a drug delivery device company.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. The area of interest is aerosol propellants for medicines.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am Director at Aptar Pharma, a drug delivery device company.
   • Government advice and other policy development: I have no involvement with government advice or policy development.
   • Paid research activities, fellowships or grants: I have no paid research activities, fellowships or grants.
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is via my employer, Aptar Pharma.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Gerallt Williams
Date: 2022-02-23

I, Ashley Woodcock, residing in United Kingdom, a Co-chair of the Technology and Economic Assessment Panel (TEAP), Member of the Medical and Chemicals Technical Options CommitteeTOC, and Co-chair of TEAP task force on decision XXXIII/5 till 31st December 2022 declare as follows:

1. I have read the Conict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Consultant Respiratory Physician and Professor of Respiratory Medicine
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have) proprietary interest in any substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I occasionally consult on new medicines for pharmaceutical companies. I publish research papers on treatments for asthma amd COPD. I give lectures on environmental matters.
   • Government advice and other policy development: I am the Clinical Lead for Sustainability for my Hospital.
   • Paid research activities, fellowships or grants: None relevant
   • Other interests: None relevant
5. The source of funding for my participation in the work of TEAP is Manchester University NHS Foundation NHS Trust, which allows me to take leave and provides travel support to attend meetings. I work voluntarily as Co-Chair of TEAP, Member of MCTOC, Co-chair of EETF and Member of RTF.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Signed:Ashley Woodcock
Date: 2022-01-24

I, Nee Sun Choong Kwet Yive, residing in Mauritius, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Associate Professor in Chemistry at the University of Mauritius. My responsibilities include teaching Physical and Analytical at undergraduate and post graduate levels and doing research in the field of environmental chemistry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. (if answer is yes describe briefly)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (if answer is yes describe briefly)
   • Employment, consultancy, directorship or other positions: None
   • Government advice and other policy development: I participated in national meetings organized by Ministry of Environment, Mauritius to phase out ODSs.
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is the Ozone Secretariat
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Nee Sun ChoongKwet Yive
Date: 2022-03-08

I, Lifei Zhang, residing in China, a Member of the Medical and Chemicals Technical Options Committee, of MBTOC till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the professor and director of Research Office of Convention Implementation Monitoring, National Research Center for Environmental Analysis and Measurement, Environmental Development Center of the Ministry of Ecology and Environment of China. My current research focuses on environmental monitoring and standardization, including monitoring related to POPs, Hg, and ODS etc. international conventions; investigation monitoring for major regions and basins in China; developing national environmental monitoring standards, environmental planning and assessment, and chemical decomposition technologies on organic compounds and it’s mechanisms.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is UNEP.
6. Pursuant to paragraph 11 oftheCOI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 ofthose Guidelines.
7. I undertake to disclose any material change to any ofthe above information, pursuant to paragraph 9 oftheCOI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations ofinterest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name: Lifei Zhang
Date: 2022-03-08